Investing.com -- Eli Lilly stock dropped 5% on Wednesday after rival Novo Nordisk announced disappointing results from its ...

Pharmaceutical company Eli Lilly is looking to roll out a daily weight loss pill for patients with obesity and type 2 ...

LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across ...

Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added health benefits, early trial results suggest. The pharmaceutical company ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial. "We are ...

(Reuters) - A large trial showed that a high dose of Eli Lilly and Co's Mounjaro helped people with type 2 diabetes who were also obese or overweight to lose nearly 16% of their body weight, or over ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still ...

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according ...

Eli Lilly has broken free from the Big Pharma pack. Fueled by sky-high expectations for the GLP-1 market, Lilly has achieved ...

Bernstein just threw fresh fuel on Eli Lilly's (LLY) never-ending rally, as the firm lifted its price target on the stock to ...